Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 17,830 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Dose level 3 Clear all

Conditions: Safety and Efficacy of Sedation Medications
Interventions: Dexmedetomidine, Propofol; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Years to 11 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza
Interventions: Oseltamivir, Placebo; Drug
Lead sponsor: Marshfield Clinic Research Foundation; Other
Eligibility: 1 Year to 79 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Marshfield, Wisconsin

Conditions: Breast Cancer
Interventions: Standard Dose Dense Doxorubucin and Cyclophosphamide, Standard Doxorubucin and Cyclophosphamide, Standard Docetaxel, Carboplatin, and Herceptin, Standard Docetaxel, Doxorubucin and Cyclophosphamide, Standard Docetaxel and Cyclophosphamide; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: FluMist; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 5 Years to 49 Years
Enrollment: 63,061 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 77
States / cities: Alameda, California • Antioch, California • Clovis, California + 49 more

Conditions: Asthma
Interventions: tiotropium bromide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more

Conditions: Stroke
Interventions: Telmisartan, Metformin, Cilostazol; Drug
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 21 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection; Drug · Procedure · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ewing's Sarcoma
Interventions: Vigil, Temozolomide, Irinotecan, Gemcitabine, Docetaxel; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Little Rock, Arkansas • Miami, Florida • New York, New York + 2 more

Conditions: Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma, Lung Neoplasms
Interventions: Drug: Hyperacute Lung Cancer Cell Vaccine; Biological
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Breast Cancer
Interventions: Palliative Radiation and Pembrolizumab; Combination Product
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Cetuximab, PD 0332991; Biological · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • Westwood, Kansas • Ann Arbor, Michigan + 2 more

Conditions: HIV Infections, AIDS
Interventions: L-carnitine, Placebo; Drug · Other
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Myelogenous Leukemia
Interventions: Gleevec (imatinib), valproic acid; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Pancreatic Cancer
Interventions: PEGPH20, Cetuximab, DW & DCE-MRI, blood draws; Drug · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Negative Pressure Therapy, Wound, Open Wound, Type II Obese Diabetic, Type II Non-Obese Diabetic
Interventions: FPP; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years to 30 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Prostate Cancer
Interventions: brachytherapy, radiation therapy; Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 8
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 5 more

Conditions: Overactive Bladder
Interventions: onaBoNT-A, Oxybutynin ER; Drug
Lead sponsor: Christopher Patrick Smith; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Brain Neoplasms, Central Nervous System Neoplasms
Interventions: TPI287, Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma, Skin Cancer
Interventions: XL888, Vemurafenib, Cobimetinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Atrial Fibrillation
Interventions: betrixaban, Warfarin; Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Anaheim, California • Colorado Springs, Colorado • Melbourne, Florida + 16 more

Conditions: Myelodysplastic Syndromes
Interventions: filgrastim, clofarabine, cytarabine, microarray analysis, biopsy; Biological · Drug · Genetic + 1 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Type 2 Diabetes Mellitus
Interventions: S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cystic Fibrosis
Interventions: Telavancin Injection; Drug
Lead sponsor: Joseph L. Kuti, PharmD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Hartford, Connecticut • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more

Search by objective public record fields.

Comparing Safety and Efficacy of Dexmedetomidine and Propofol

Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza

Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens

A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Vaccine Treatment for Advanced Non-Small Cell Lung Cancer

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

L-Carnitine to Treat Fatigue in AIDS Patients

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

Nutritional Regulation of Wound Inflammation: Part III

Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer

Telavancin Pharmacokinetics in Cystic Fibrosis Patients